Retrovir (Zidovudine, AZT)
| Brand Name: |
Retrovir |
| Generic Name: |
Zidovudine, AZT |
| Adult Single Dose: |
One 300-mg tablet twice a day; or one 200-mg tablet three times a day |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- Zidovudine (Retrovir, AZT) (February 23, 2013)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Retrovir (Zidovudine, AZT) (September 13, 2012)
From AIDSinfo
- Retrovir (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Retrovir (Zidovudine, AZT) IV Infusion (PDF) (November 2011)
From ViiV Healthcare
- Patient Information About Retrovir (Zidovudine, AZT) Oral Solution (PDF) (November 2011)
From ViiV Healthcare
- AZT (Retrovir, Zidovudine, ZDV) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- AZT (zidovudine, Retrovir) (October 19, 2006)
From AIDS Treatment Data Network
- Retrovir (Zidovudine) (November 2005)
To read PDF, click here.
From The Center for AIDS
- Approval of Generic Zidovudine (September 20, 2005)
From U.S. Food and Drug Administration
- Drug Interactions: Zidovudine (August 2004)
From Project Inform
- AZT: A Hard Pill To Swallow! Some Reasons for It, Some Against (Winter 1996)
In Women Alive Newsletter, from Women Alive
- Antiretroviral Therapy Positives and Negatives (Autumn 1995)
From ACT UP/Philadelphia's Standard of Care document.
In Women Alive Newsletter, from Women Alive
News
- FDA Approves Generic Formulations of Lamivudine and Zidovudine Tablets and Nevirapine Tablets and Oral Suspension (May 25, 2012)
From U.S. Food and Drug Administration
- Generic Drug Maker Receives FDA, PEPFAR Approval for Drug to Treat HIV-Positive Children (March 14, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Retrovir (Zidovudine) for Pediatrics (January/February 2010)
In Positively Aware, from Test Positive Aware Network
- New Dosing Recommendations Retrovir (Zidovudine) Syrup for HIV-Infected Infants (November 6, 2009)
From U.S. Food and Drug Administration
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- FDA Approves First Generic HIV/AIDS Drug in Capsule Form for United States Market (March 31, 2006)
From U.S. Food and Drug Administration
- A Bitter-Sweet Pill (March 2006)
The first ever HIV drug, AZT, has a checkered history. What's next for the drug as it comes off patent in the UK?.
From Positive Nation
- FDA Approves Four Generic Forms of Zidovudine for U.S. Sales After Retrovir's Patent Expires (September 21, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon (September 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Zidovudine Generic Oral Solution Approved in United States (September 20, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
VIEW ALL ARTICLES
Research
- HIV Defense Mechanisms Against AZT Found (September 20, 2010)
In Softpedia
- Studies Raise Possible Long-Term Concern for Infants Exposed to Retrovir in Womb (April 16, 2007)
From aidsmap.com
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV-Positive Mothers Should Continue AZT Prophylaxis After Childbirth, Study Says (October 3, 2004)
A study finds a brief jump in breast milk viral load following AZT cessation.
From aidsmap.com
- Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
- Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
On TheBodyPRO.com
- No PK Interaction Seen Between FTC and AZT or Tenofovir (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
